Susoctocog alfa, Recombinant porcine BDD antihaemophilic factor VIII (FVIII)

Specification

• Cat#: THP-0093
• Product Name: Susoctocog alfa, Recombinant porcine BDD antihaemophilic factor VIII (FVIII)
• Description: Recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker.
• Sequences: Not Available
• Species: Porcine
• Molecular Weight: 170000.0 Da (Approximate, B-Domain deleted)
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 1339940-90-7
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 500U/ml

Pharmaceutical Information

• Pharmaceutical Application: Susoctocog alfa
• Applications: Indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.
• Examples of Clinical Use: Acquired hemophilia A
• Pharmacodynamics: Following the product administration, the activated partial thromboplastin time (aPTT) is expected to normalize indicating restored biological activity of factor VIII and normal clotting time. In a prospective, open-label clinical trail involving 28 subjects with acquired haemophilia A, all subjects had a positive response to treatment for the initial bleeding episodes at 24 hours after dosing where bleeding was either stopped or substantially reduced.
• Mechanism of action: Factor VIII circulates in the plasma as a hemostatically active protein complex that consists of factor VIII and a large carrier protein von Willebrand factor via a non-covalent binding interaction. This protein complex remains inactive until the coagulation cascade is activated which in turn activates factor VIII to be released from factor VIII/von Willebrand factor complex. Activated factor VIII acts as a cofactor for factor IX-mediated conversion of factor X to activated factor X. Activated factor X is critical in converting prothrombin into thrombin and sequentially, thrombin converts fibrinogen to fibrin for the formation of a blood clot.
• Affected organisms: Not Available
• Targets: Target 1. von Willebrand factor